Showing results (191-200 of 220) with videos related to

Sort By:
Pageof 22
Nature Medicine|October 13, 2022
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trialRichard D Carvajal, Marcus O Butler, Alexander N Shoushtari, et al.
Journal of Leukocyte Biology|March 11, 2024
The ecto-enzyme CD38 modulates CD4T cell immunometabolic responses and participates in HIV pathogenesisFernando Díaz-Basilio, Moisés Vergara-Mendoza, Jessica Romero-Rodríguez, et al.
Cancers|November 9, 2024
Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in EuropeMichael Weichenthal, Joanna Mangana, Iva Gavrilova, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|March 1, 2018
Quantum Crystallography: Current Developments and Future PerspectivesAlessandro Genoni, Lukas Bučinský, Nicolas Claiser, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2018
An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring systemJames Larkin, Michael P Brown, Ana M Arance, et al.
Cancers|September 9, 2023
Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced MelanomaLucía Trilla-Fuertes, Angelo Gámez-Pozo, Guillermo Prado-Vázquez, et al.
Nature Communications|December 2, 2021
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trialMaria Gonzalez-Cao, Clara Mayo de Las Casas, Juana Oramas, et al.
Journal of Clinical Medicine|April 30, 2021
Development and Validation of an Early Mortality Risk Score for Older Patients Treated with Chemotherapy for CancerJaime Feliu, Alvaro Pinto, Laura Basterretxea, et al.
Cancer Immunology, Immunotherapy : CII|April 28, 2026
Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapyAngelo Gámez-Pozo, Lucía Trilla-Fuertes, Fernando Becerril-Gómez, et al.
British Journal of Cancer|May 7, 2025
A prognostic microRNA-based signature for localized clear cell renal cell carcinoma: the Bio-miR studyÁlvaro Pinto-Marín, Lucía Trilla-Fuertes, Jesús Miranda Poma, et al.
Pageof 22